JP2009530302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530302A5 JP2009530302A5 JP2009500517A JP2009500517A JP2009530302A5 JP 2009530302 A5 JP2009530302 A5 JP 2009530302A5 JP 2009500517 A JP2009500517 A JP 2009500517A JP 2009500517 A JP2009500517 A JP 2009500517A JP 2009530302 A5 JP2009530302 A5 JP 2009530302A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound according
- disease
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 22
- 201000010099 disease Diseases 0.000 claims 17
- 208000002193 Pain Diseases 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 208000004296 neuralgia Diseases 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 10
- -1 sulfate ester Chemical class 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 208000037765 diseases and disorders Diseases 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 8
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 230000001404 mediated effect Effects 0.000 claims 8
- 208000023275 Autoimmune disease Diseases 0.000 claims 7
- 208000020925 Bipolar disease Diseases 0.000 claims 6
- 206010020751 Hypersensitivity Diseases 0.000 claims 6
- 208000003251 Pruritus Diseases 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 208000023504 respiratory system disease Diseases 0.000 claims 6
- 206010029240 Neuritis Diseases 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 230000000155 isotopic effect Effects 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 201000008482 osteoarthritis Diseases 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 4
- 206010019233 Headaches Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 125000004442 acylamino group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 4
- 150000001540 azides Chemical class 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 231100000869 headache Toxicity 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 230000007794 irritation Effects 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 4
- 150000003457 sulfones Chemical class 0.000 claims 4
- 150000003462 sulfoxides Chemical class 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- 208000004371 toothache Diseases 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 3
- 206010069632 Bladder dysfunction Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 208000006561 Cluster Headache Diseases 0.000 claims 3
- 208000030814 Eating disease Diseases 0.000 claims 3
- 208000034347 Faecal incontinence Diseases 0.000 claims 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 3
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010065390 Inflammatory pain Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010043269 Tension headache Diseases 0.000 claims 3
- 208000008548 Tension-Type Headache Diseases 0.000 claims 3
- 206010046543 Urinary incontinence Diseases 0.000 claims 3
- 208000005298 acute pain Diseases 0.000 claims 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000004983 autoimmune atherosclerosis Diseases 0.000 claims 3
- 201000004982 autoimmune uveitis Diseases 0.000 claims 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 208000028683 bipolar I disease Diseases 0.000 claims 3
- 230000036772 blood pressure Effects 0.000 claims 3
- 201000007637 bowel dysfunction Diseases 0.000 claims 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 235000014632 disordered eating Nutrition 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 206010013990 dysuria Diseases 0.000 claims 3
- 206010014599 encephalitis Diseases 0.000 claims 3
- 230000009610 hypersensitivity Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 230000007803 itching Effects 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 230000003959 neuroinflammation Effects 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 230000008085 renal dysfunction Effects 0.000 claims 3
- 230000000241 respiratory effect Effects 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 2
- 208000012790 cranial neuralgia Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 claims 2
- 208000036273 reactive airway disease Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- WITJHZRCLVXYCA-UHFFFAOYSA-N 3h-1,2-benzodioxepine Chemical compound C1=CCOOC2=CC=CC=C21 WITJHZRCLVXYCA-UHFFFAOYSA-N 0.000 claims 1
- 206010003399 Arthropod bite Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010006784 Burning sensation Diseases 0.000 claims 1
- 206010008334 Cervicobrachial syndrome Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000001375 Facial Neuralgia Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 206010049949 Intercostal neuralgia Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000002472 Morton Neuroma Diseases 0.000 claims 1
- 208000020059 Morton neuralgia Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010068106 Occipital neuralgia Diseases 0.000 claims 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 claims 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000004078 Snake Bites Diseases 0.000 claims 1
- 208000003589 Spider Bites Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- 150000005528 benzodioxoles Chemical class 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 229960002504 capsaicin Drugs 0.000 claims 1
- 235000017663 capsaicin Nutrition 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 1
- 150000002790 naphthalenes Chemical class 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 210000003254 palate Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 claims 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical class C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 claims 1
- 208000019629 polyneuritis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 239000003491 tear gas Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Applications Claiming Priority (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78277606P | 2006-03-16 | 2006-03-16 | |
| US78277506P | 2006-03-16 | 2006-03-16 | |
| US78292306P | 2006-03-16 | 2006-03-16 | |
| US78292206P | 2006-03-16 | 2006-03-16 | |
| US78359006P | 2006-03-16 | 2006-03-16 | |
| US78330406P | 2006-03-16 | 2006-03-16 | |
| US78297306P | 2006-03-16 | 2006-03-16 | |
| US78312106P | 2006-03-16 | 2006-03-16 | |
| US78374806P | 2006-03-16 | 2006-03-16 | |
| US78278206P | 2006-03-16 | 2006-03-16 | |
| US78278106P | 2006-03-16 | 2006-03-16 | |
| US60/782,923 | 2006-03-16 | ||
| US60/783,121 | 2006-03-16 | ||
| US60/783,748 | 2006-03-16 | ||
| US60/782,922 | 2006-03-16 | ||
| US60/782,973 | 2006-03-16 | ||
| US60/782,782 | 2006-03-16 | ||
| US60/783,304 | 2006-03-16 | ||
| US60/782,775 | 2006-03-16 | ||
| US60/783,590 | 2006-03-16 | ||
| US60/782,776 | 2006-03-16 | ||
| US60/782,781 | 2006-03-16 | ||
| US83141606P | 2006-07-17 | 2006-07-17 | |
| US60/831,416 | 2006-07-17 | ||
| US84699306P | 2006-09-25 | 2006-09-25 | |
| US60/846,993 | 2006-09-25 | ||
| US91808607P | 2007-03-15 | 2007-03-15 | |
| US60/918,086 | 2007-03-15 | ||
| PCT/US2007/006685 WO2007109160A2 (en) | 2006-03-16 | 2007-03-16 | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009530302A JP2009530302A (ja) | 2009-08-27 |
| JP2009530302A5 true JP2009530302A5 (enExample) | 2011-03-17 |
| JP5306986B2 JP5306986B2 (ja) | 2013-10-02 |
Family
ID=38522992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500517A Expired - Fee Related JP5306986B2 (ja) | 2006-03-16 | 2007-03-16 | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8779144B2 (enExample) |
| EP (1) | EP1937643B1 (enExample) |
| JP (1) | JP5306986B2 (enExample) |
| BR (1) | BRPI0709596A2 (enExample) |
| CA (1) | CA2645551C (enExample) |
| DK (1) | DK1937643T3 (enExample) |
| ES (1) | ES2596532T3 (enExample) |
| MX (1) | MX2008011919A (enExample) |
| WO (1) | WO2007109160A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7402596B2 (en) * | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| JP2010520875A (ja) * | 2007-03-09 | 2010-06-17 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 |
| JP2011509296A (ja) * | 2008-01-09 | 2011-03-24 | レノビス， インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体およびそれを使用する薬学的組成物および方法 |
| AU2009228649B2 (en) | 2008-03-25 | 2014-05-22 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
| CN112079769A (zh) * | 2008-04-23 | 2020-12-15 | 里格尔药品股份有限公司 | 用于治疗代谢障碍的甲酰胺化合物 |
| CA2744383C (en) | 2008-11-21 | 2017-04-25 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
| WO2010118921A1 (en) | 2009-04-14 | 2010-10-21 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| JP2013526496A (ja) | 2010-05-14 | 2013-06-24 | アフェクティス ファーマシューティカルズ アーゲー | Ｐ２ｘ７ｒ拮抗剤の新規調製方法 |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| JP5955957B2 (ja) | 2011-07-22 | 2016-07-20 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| US9409917B2 (en) | 2012-01-20 | 2016-08-09 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
| TWI612034B (zh) | 2012-12-12 | 2018-01-21 | 愛杜西亞製藥有限公司 | 作爲ｐ２ｘ７受體拮抗劑之吲哚羧醯胺衍生物 |
| US9556117B2 (en) | 2012-12-18 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as P2X7 receptor antagonists |
| ES2616114T3 (es) | 2013-01-22 | 2017-06-09 | Actelion Pharmaceuticals Ltd. | Derivados de amida heterocíclica como antagonistas del receptor P2X7 |
| CN104918946B (zh) | 2013-01-22 | 2017-03-29 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| WO2023179542A1 (en) * | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3942893A1 (de) | 1989-12-23 | 1991-06-27 | Bayer Ag | Heterocyclische verbindungen |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5336674A (en) | 1993-01-27 | 1994-08-09 | Merck & Co., Inc. | 2-phenanthridinyl carbaphenem antibacterial agent |
| GB9310700D0 (en) | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Novel composition |
| US5670517A (en) * | 1993-11-30 | 1997-09-23 | Lg Chemical Limited | Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof |
| WO1997048683A1 (en) * | 1996-06-17 | 1997-12-24 | Smithkline Beecham Plc | Substituted benzamide derivatives and their use as anticonvulsants |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| CN1930160B (zh) | 2004-03-09 | 2011-11-16 | 默沙东公司 | Hiv整合酶抑制剂 |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| SE0401345D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
| AU2005261487A1 (en) | 2004-07-12 | 2006-01-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
| PE20060621A1 (es) | 2004-09-07 | 2006-06-29 | Smithkline Beecham Corp | 1,3-diaminas aciclicas como agonistas de los receptores del canal trpv4 |
| JP2006220522A (ja) | 2005-02-10 | 2006-08-24 | National Institute For Materials Science | Ｄｎａとｄｎａ結合分子の結合様式の判定方法及びその判定に使用する試料の作製方法 |
| US20060223849A1 (en) | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| US7402596B2 (en) * | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| WO2006104141A1 (ja) | 2005-03-29 | 2006-10-05 | Shionogi & Co., Ltd. | ３－プロペニルセフェム誘導体 |
| CA2607151C (en) | 2005-05-10 | 2012-06-19 | Merck & Co., Inc. | Hiv integrase inhibitors |
| FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| AU2006269504A1 (en) | 2005-07-08 | 2007-01-18 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
| JP2009507855A (ja) | 2005-09-08 | 2009-02-26 | スミスクライン・ビーチャム・コーポレイション | 非環式１，４−ジアミンおよびその使用 |
| TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
| JP2010520875A (ja) * | 2007-03-09 | 2010-06-17 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 |
-
2007
- 2007-03-16 CA CA2645551A patent/CA2645551C/en not_active Expired - Fee Related
- 2007-03-16 DK DK07753320.6T patent/DK1937643T3/en active
- 2007-03-16 US US11/722,514 patent/US8779144B2/en not_active Expired - Fee Related
- 2007-03-16 JP JP2009500517A patent/JP5306986B2/ja not_active Expired - Fee Related
- 2007-03-16 ES ES07753320.6T patent/ES2596532T3/es active Active
- 2007-03-16 WO PCT/US2007/006685 patent/WO2007109160A2/en not_active Ceased
- 2007-03-16 MX MX2008011919A patent/MX2008011919A/es active IP Right Grant
- 2007-03-16 BR BRPI0709596-1A patent/BRPI0709596A2/pt not_active Application Discontinuation
- 2007-03-16 EP EP07753320.6A patent/EP1937643B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009530302A5 (enExample) | ||
| JP2009541206A5 (enExample) | ||
| JP2009530304A5 (enExample) | ||
| JP2010520875A5 (enExample) | ||
| JP2010524930A5 (enExample) | ||
| JP5306986B2 (ja) | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 | |
| JP2008534511A5 (enExample) | ||
| ES2639621T3 (es) | Derivados de fenilamida del ácido 4-(bencil)-piperazina-1-carboxílico y compuestos relacionados como moduladores de la amida hidrolasa de ácidos grasos (FAAH) para el tratamiento de la ansiedad, el dolor y otras afecciones | |
| JP2007509043A5 (enExample) | ||
| JP2008546639A5 (enExample) | ||
| JP5306987B2 (ja) | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 | |
| IL255752A (en) | Novel anti-inflammatory agents | |
| JP2010523562A5 (enExample) | ||
| ES2664810T3 (es) | Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA | |
| EA200901162A1 (ru) | Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2 | |
| KR20140027160A (ko) | 치환된 디아미노카르복스아미드 및 디아미노카르보니트릴 피리미딘, 그의 조성물, 및 그를 사용하는 치료 방법 | |
| JP2011503072A5 (enExample) | ||
| HRP20200681T1 (hr) | Ciklički eter pirazol-4-il-heterociklil-karboksamidni spojevi i postupci njihove upotrebe | |
| ATE517868T1 (de) | Pyrazinverbindungen, ihre verwendung und herstellungsverfahren | |
| HRP20110097T1 (hr) | Derivati fenilpirazola kao nesteroidni ligandi glukokortikoidnih receptora | |
| JP7167236B2 (ja) | せん妄の予防または治療剤 | |
| ES2825348T3 (es) | Compuestos y composición farmacéutica asociados al sistema ubiquitinación-proteasoma | |
| JP2014520810A5 (enExample) | ||
| JP2012509332A5 (enExample) | ||
| JP2018529639A (ja) | アミノナフトキノン化合物、および疾患におけるユビキチン化−プロテアソーム系をブロックするための薬学的組成物 |